NWS
38
6
STZ
45
-3
HOG
26
-3
SLG
23
6
ABBV
62
3
AA
63
-4
AVY
50
-3
FLR
29
-3
DG
55
-2
LEN
17
-2
CVX
49
-6
O
53
-2
NEM
63
7
PBI
62
16
F
60
17
MAT
34
-3
REGN
56
5
CCI
30
2
M
53
16
CMI
63
3
NWS
38
6
STZ
45
-3
HOG
26
-3
SLG
23
6
ABBV
62
3
AA
63
-4
AVY
50
-3
FLR
29
-3
DG
55
-2
LEN
17
-2
CVX
49
-6
O
53
-2
NEM
63
7
PBI
62
16
F
60
17
MAT
34
-3
REGN
56
5
CCI
30
2
M
53
16
CMI
63
3
Financhill
Back

Basilea Pharmaceutica AG 10K Form

Buy
51

BPMUF
Basilea Pharmaceutica AG

Last Price:
$71.00
Seasonality Move:
3.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BPMUF News And Ratings

See the #1 stock for the next 7 days that we like better than BPMUF

BPMUF Financial Statistics

Sales & Book Value

Annual Sales: $279.8M
Cash Flow: $0
Price / Cash Flow: 13.15
Annual Sales: $1.54
Price / Book: 9.27

Profitability

EPS (TTM): 3.67230
Net Income (TTM): $48.9M
Gross Margin: $232.5M
Return on Equity: -15.42%
Return on Assets: -0.54%

Basilea Pharmaceutica AG Earnings Forecast

Key Basilea Pharmaceutica AG Financial Ratios

  • The Gross Profit Margin over the past 24 years for BPMUF is 83.08%.
  • The Selling, General & Administrative Expenses for BPMUF have been equal to 15.33% of Gross Profit Margin.
  • The Research & Development expenses have been 45.57% of Revenue.
  • The Interest Expense is 8.34% of Operating Income.
  • The Net Earning history of BPMUF is 17.32% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 12 years.

Basilea Pharmaceutica AG Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Biotechnology
Sector: Health Care
Current Symbol: BPMUF
Website: basilea.com

Debt

Debt-to-Equity Ratio: 5.7
Current Ratio: 4.1
Quick Ratio: 2.96

Price-to-Earnings

Trailing P/E Ratio: 18.77
Forward P/E Ratio: 0

BPMUF Technical Analysis vs Fundamental Analysis

Buy
51
Basilea Pharmaceutica AG (BPMUF) is a Buy

Is Basilea Pharmaceutica AG a Buy or a Sell?